• Ceribell’s third-quarter 2026 net loss widened 59% year over year to $21.35 million.
• Revenue rose 30% year over year to $29.34 million, driven primarily by increased utilization and adoption of the Ceribell System.
• Operating expenses climbed 36% year over year to $46.89 million, primarily attributable to commercial expansion, research investments, stock-based compensation and legal costs.
• The company announced the full launch of its delirium monitoring solution following a successful commercial pilot.
• Full-year 2026 revenue guidance increased to $115 million–$117 million, excluding material contributions from neonate, pediatric or delirium products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ceribell Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031605PRIMZONEFULLFEED9869454) on November 03, 2026, and is solely responsible for the information contained therein.